Literature DB >> 12079901

Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis.

T Avcin1, R Cimaz, F Falcini, F Zulian, G Martini, G Simonini, V Porenta-Besic, G Cecchini, M O Borghi, P L Meroni.   

Abstract

BACKGROUND: Antibodies against cyclic citrullinated peptide (anti-CCP) are considered to be specific for rheumatoid arthritis (RA).
OBJECTIVE: To assess the clinical significance of anti-CCP in a cohort of patients with juvenile idiopathic arthritis (JIA).
METHODS: Anti-CCP were tested by an enzyme linked immunosorbent assay (ELISA) in serum samples from 109 patients with JIA (30 boys, 79 girls), with a mean age of 8.7 years (range 0.6-20.3) and mean disease duration of 3.6 years (range 3 months to 15.6 years). As control groups, anti-CCP were also tested in sera of 30 healthy children, 25 patients with juvenile onset systemic lupus erythematosus (SLE), and 50 adult patients (30 with RA, 20 with SLE).
RESULTS: Positive anti-CCP values were found in sera of two patients with JIA (2%), one with polyarthritis, and one with oligoarthritis. Statistical analysis showed that anti-CCP were not associated with the presence of antinuclear antibodies, raised erythrocyte sedimentation rate, or erosions. In the control groups, none of the patients with juvenile onset SLE and only one of 20 adults with SLE were positive for anti-CCP, but 19/30 (63%) adults with RA showed anti-CCP positivity.
CONCLUSIONS: Anti-CCP can be detected in children with JIA, but are less frequently present than in adults with RA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079901      PMCID: PMC1754144          DOI: 10.1136/ard.61.7.608

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

1.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.

Authors:  G A Schellekens; H Visser; B A de Jong; F H van den Hoogen; J M Hazes; F C Breedveld; W J van Venrooij
Journal:  Arthritis Rheum       Date:  2000-01

2.  The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin.

Authors:  C Masson-Bessière; M Sebbag; E Girbal-Neuhauser; L Nogueira; C Vincent; T Senshu; G Serre
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

3.  Anti-keratin antibodies in patients with juvenile idiopathic arthritis.

Authors:  I Hromadníková; P Vavrincova; K Stechova; D Hridelova
Journal:  Clin Exp Rheumatol       Date:  2001 Jul-Aug       Impact factor: 4.473

4.  Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  R Mediwake; D A Isenberg; G A Schellekens; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

5.  Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis.

Authors:  C C Reparon-Schuijt; W J van Esch; C van Kooten; G A Schellekens; B A de Jong; W J van Venrooij; F C Breedveld; C L Verweij
Journal:  Arthritis Rheum       Date:  2001-01

6.  Clinical significance of anticardiolipin antibodies in juvenile idiopathic arthritis.

Authors:  C R Serra; S H Rodrigues; N P Silva; F R Sztajnbok; L E Andrade
Journal:  Clin Exp Rheumatol       Date:  1999 May-Jun       Impact factor: 4.473

7.  The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis.

Authors:  E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel
Journal:  Arthritis Rheum       Date:  2000-08

8.  The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis.

Authors:  C H van Jaarsveld; E J ter Borg; J W Jacobs; G A Schellekens; F H Gmelig-Meyling; C van Booma-Frankfort; B A de Jong; W J van Venrooij; J W Bijlsma
Journal:  Clin Exp Rheumatol       Date:  1999 Nov-Dec       Impact factor: 4.473

9.  Estimation of anticardiolipin antibodies, anti-beta2 glycoprotein I antibodies and lupus anticoagulant in a prospective longitudinal study of children with juvenile idiopathic arthritis.

Authors:  T Avcin; A Ambrozic; B Bozic; M Accetto; T Kveder; B Rozman'
Journal:  Clin Exp Rheumatol       Date:  2002 Jan-Feb       Impact factor: 4.473

10.  Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset.

Authors:  R Goldbach-Mansky; J Lee; A McCoy; J Hoxworth; C Yarboro; J S Smolen; G Steiner; A Rosen; C Zhang; H A Ménard; Z J Zhou; T Palosuo; W J Van Venrooij ; R L Wilder; J H Klippel; H R Schumacher; H S El-Gabalawy
Journal:  Arthritis Res       Date:  2000-03-31
View more
  15 in total

1.  Evaluation of anti-cyclic citrullinated peptide antibodies may be beneficial in RF-negative juvenile idiopathic arthritis patients.

Authors:  Mihaela Spârchez; Nicolae Miu; Claudia Bolba; Mihaela Iancu; Zeno Spârchez; Simona Rednic
Journal:  Clin Rheumatol       Date:  2015-05-21       Impact factor: 2.980

2.  Anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis.

Authors:  R Gupta; M M Thabah; B Vaidya; S Gupta; R Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2010-02-05       Impact factor: 1.967

Review 3.  The role of anti-cyclic cytrullinate antibodies testing in rheumatoid arthritis.

Authors:  Cristiano Alessandri; Roberta Priori; Mariagrazia Modesti; Riccardo Mancini; Guido Valesini
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

Review 4.  Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology.

Authors:  Reema H Syed; Brooke E Gilliam; Terry L Moore
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.592

5.  Onset of polyarticular juvenile idiopathic arthritis with both anti-cyclic citrullinated peptide antibodies and rheumatoid factor in a 3-year-old girl.

Authors:  Kozo Yasui; Sonoko Sakata; Hideaki Ochi; Shinji Itamura; Kenta Hirai; Mieko Takenaka; Osamu Mitani; Kazunori Ogawa; Kuniaki Iyoda
Journal:  Pediatr Rheumatol Online J       Date:  2012-12-13       Impact factor: 3.054

6.  Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis.

Authors:  Anne E Tebo; Troy Jaskowski; K Wayne Davis; April Whiting; Bronte Clifford; Andrew Zeft; Bernadette McNally; Harry R Hill; John Bohnsack; Sampath Prahalad
Journal:  Pediatr Rheumatol Online J       Date:  2012-08-29       Impact factor: 3.054

7.  B-cell pathology in juvenile idiopathic arthritis.

Authors:  V Wiegering; H J Girschick; H Morbach
Journal:  Arthritis       Date:  2010-12-02

8.  Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris.

Authors:  Szandra Dalmády; Mária Kiss; László Képíró; László Kovács; Gábor Sonkodi; Lajos Kemény; Rolland Gyulai
Journal:  Clin Dev Immunol       Date:  2013-03-18

9.  Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis.

Authors:  Brooke E Gilliam; Anil K Chauhan; Terry L Moore
Journal:  Pediatr Rheumatol Online J       Date:  2013-08-29       Impact factor: 3.054

Review 10.  The immune response to citrullinated proteins in patients with rheumatoid arthritis: genetic, clinical, technical, and epidemiological aspects.

Authors:  Allan S Wiik
Journal:  Clin Rev Allergy Immunol       Date:  2007-02       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.